Table 6.
Area under the curve comparisons for plasma and CSF biomarkers for the identification of amyloid-PET positivity in the BioFINDER-2 cohort
| Immunoassay | MS | 95% CI of difference | p-value | |
|---|---|---|---|---|
| Amyloid-PET positivity | ||||
| p-tau181 | 89% (84–94%) | 73% (66–80%) | 11 – 20% | < 0.000 |
| p-tau217 | 93% (89–96%) | 89% (84–94%) | 1 – 7% | 0.023 |
| p-tau231 | 90% (85–94%) | 84% (79–90%) | 0 – 11% | 0.052 |
| Amyloid-PET positivity in CU individuals | ||||
| p-tau181 | 93% (89–97%) | 76% (67–85%) | 10 – 23% | < 0.000 |
| p-tau217 | 96% (94–99%) | 92% (87–97%) | 1 – 8% | 0.020 |
| p-tau231 | 93% (89–97%) | 87% (81–94%) | -1 – 12% | 0.092 |
| Amyloid-PET positivity in CI individuals | ||||
| p-tau181 | 84% (76–93%) | 72% (60–84%) | 4 – 20% | 0.003 |
| p-tau217 | 86% (78–94%) | 82% (72–92%) | -2 – 10% | 0.152 |
| p-tau231 | 85% (75–95%) | 78% (67–89%) | -5 – 18% | 0.247 |
AUCs were compared using DeLong’s test. Values in parentheses represent 95% Confidence intervals